Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINOVA-3: Trebananib in First-line Ovarian Cancer
NCT01493505Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jan 2012
- Primary completion
- Mar 2016
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing AMG 386 Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Started Jan 2012; status: terminated.
02
Drugs
trebananib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01493505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01493505.